No CrossRef data available.
Article contents
Reasons to choose a long acting antipsychotic and tolerability
Published online by Cambridge University Press: 23 March 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
Aripiprazole depot is an atypical antipshycotic used to treat positive and negative symptoms of psychosis or acute mania.
Aim
Describe the reason why psychiatrists switch the current antipsychotic treatment on to aripiprazol depot, its tolerability and the reasons to stop aripiprazol depot treatment.
Methods
Descriptive analysis based on a sample of 37 patients, aged 18–65 years, treated during one year with antipsychotics at two community mental health units.
Results
Switching on to aripiprazole depot principal reasons: promote adherence (25%), persistence of symptoms (25%) and high levels of prolactin or sexual dysfunction (16.66%):
– side effects of aripiprazole depot: insomnia (11.11%), inquietude (8.33%), sexual dysfunction (2.77%) and hypertensive crisis during administration (2.77%);
– 83.33% of the patients are still taking it after one year. The most common reasons to stop or change it were the presence of secondaries (11.11%) and clinical exacerbation (5.55%).
Conclusions
Aripiprazole depot is well tolerated (even better than other antipsychotics). Common side effects are not severe and appear in a small percent of patients.
Disclosure of interest
The authors have not supplied their declaration of competing interest.
- Type
- e-Poster Viewing: Schizophrenia and other psychotic disorders
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. s822
- Copyright
- Copyright © European Psychiatric Association 2017
You have
Access
Comments
No Comments have been published for this article.